The short version of angiotensin IV fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-10. Anything still debated is marked as such rather than presented as settled.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
=== Homozygous Hb Lepore === Those homozygous (Hb LeporeLepore; a very rare situation) or compound heterozygous (Hb Lepore-Β-thalassaemia) might suffer from a severe anaemia. They should be managed in a comprehensive multi-disciplinary program of care. Management includes a regular course of blood transfusions, although the clinical severity in compound (double) heterozygotes can range from minor to major, depending on the combination of genes that have caused the condition.
=== Available forms === OHPH was provided as a 125 mg/1 mL oil solution for use by intramuscular injection. In addition to single-drug preparations, OHPH has also been used in a number of multi-drug formulations. It was used in Tocogestan, a combination of 50 mg progesterone, 200 mg OHPH, and 250 mg α-tocopherol palmitate (vitamin E) in oil solution for use by intramuscular injection. It was also used in Triormon Depositum (estradiol dibutyrate, testosterone caproate, and OHPH) and Trioestrine Retard (estradiol diundecylate, testosterone cyclohexylpropionate, and OHPH). OHPH was a component of the experimental preparation Trophobolene (or Trophoboline), which also contained estrapronicate (estradiol nicotinate propionate) and nandrolone undecanoate, as well.
The process of selecting appropriate deep final repositories for high-level waste and spent fuel is now underway in several countries with the first expected to be commissioned sometime after 2010. The basic concept is to locate a large, stable geologic formation and use mining technology to excavate a tunnel, or use large-bore tunnel boring machines (similar to those used to drill the Channel Tunnel from England to France) to drill a shaft 500 to 1,000 metres (1,600 to 3,300 ft) below the surface where rooms or vaults can be excavated for disposal of high-level radioactive waste. The goal is to permanently isolate nuclear waste from the human environment. Many people remain uncomfortable with the immediate stewardship cessation of this disposal system, suggesting perpetual management and monitoring would be more prudent. Because some radioactive species have half-lives longer than one million years, even very low container leakage and radionuclide migration rates must be taken into account. Moreover, it may require more than one half-life until some nuclear materials lose enough radioactivity to cease being lethal to living things. A 1983 review of the Swedish radioactive waste disposal program by the National Academy of Sciences found that country's estimate of several hundred thousand years—perhaps up to one million years—being necessary for waste isolation "fully justified." The proposed land-based subductive waste disposal method disposes of nuclear waste in a subduction zone accessed from land and therefore is not prohibited by international agreement.
Sources: en.wikipedia.org
=== Risks === Dry needling is considered invasive. Invasive treatments are associated with infections and cutaneous infections, which can be avoided, however, by using good aseptic (sterile) technique. Nonetheless, the procedure is increasing in popularity despite the unanswered questions regarding its overall effectiveness and safety. Mild adverse events following dry needling are commonly bleeding, bruising, and pain. Severe adverse effects include pneumothorax, injury to the central nervous system and spine, and blood-borne infection transmission. The American Medical Association made a press release in 2016 that said physical therapists and other non-physicians practicing dry needling should – at a minimum – have standards that are similar to the ones for training, certification, and continuing education that exist for acupuncture. AMA board member Russell W. H. Kridel, MD: "Lax regulation and nonexistent standards surround this invasive practice. For patients' safety, practitioners should meet standards required for licensed acupuncturists and physicians." Additional adverse effects of dry needling include cardiac tamponade and hematoma. During a recent study, a self-reported survey of almost 230,000 people, 8.6% (19726 patients) reported experiencing at least one adverse effect. 2.2% (4,963 patients) reported an adverse effect that required further treatment. However, since this study was based on the patient's self-reporting rather than actual incidence, the collective findings cited above are probably lower than the actual incidence.
=== Direct calorimetry of combustion === The first determinations of the energy content of food were made by burning a dried sample in a bomb calorimeter and measuring the temperature change in the water surrounding the apparatus, a method known as direct calorimetry.
== Nomenclature == This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-NH group of donors with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is N5-(L-1-carboxyethyl)-L-ornithine:NADP+ oxidoreductase (L-ornithine-forming). Other names in common use include 5-N-(L-1-carboxyethyl)-L-ornithine:NADP+ oxidoreductase, and (L-ornithine-forming).
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.